Preliminary study on the effects of enrofloxacin, flunixin meglumine and pegbovigrastim on Mycoplasma bovis pneumonia

Mycoplasma bovis is a causative agent of disease in cattle causing many clinical conditions. Currently there are no commercial M. bovis vaccines in Europe and treatment is difficult with decreased antimicrobial susceptibility of M. bovis field isolates. Using an M. bovis calf infection model the eff...

Full description

Saved in:
Bibliographic Details
Published in:BMC veterinary research 2019-10, Vol.15 (1), p.371-371, Article 371
Main Authors: Dudek, Katarzyna, Bednarek, Dariusz, Ayling, Roger D, Kycko, Anna, Reichert, Michał
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - therapeutic use
Animals
Anti-Bacterial Agents - therapeutic use
Anti-inflammatory agents
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
antibiotic resistance
calves
Carprofen
Cattle
cattle diseases
Cattle Diseases - drug therapy
Cattle Diseases - microbiology
Clonixin - analogs & derivatives
Clonixin - therapeutic use
Diagnosis
Drug Therapy, Combination - veterinary
enrofloxacin
Enrofloxacin - therapeutic use
etiological agents
Europe
Female
Flunixin
Fluoroquinolones
Granulocyte Colony-Stimulating Factor - therapeutic use
Health aspects
Immune response
Immunotherapy
Infection
lungs
Mycoplasma bovis
Mycoplasma bovis - drug effects
Mycoplasma Infections - drug therapy
Mycoplasma Infections - veterinary
nonsteroidal anti-inflammatory agents
Pegbovigrastim
Pneumonia
Pneumonia - drug therapy
Pneumonia - veterinary
Recombinant Proteins - therapeutic use
Risk factors
therapeutics
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mycoplasma bovis is a causative agent of disease in cattle causing many clinical conditions. Currently there are no commercial M. bovis vaccines in Europe and treatment is difficult with decreased antimicrobial susceptibility of M. bovis field isolates. Using an M. bovis calf infection model the effectiveness of enrofloxacin given alone; in combination with flunixin meglumine, a nonsteroidal anti-inflammatory drug; and a group with an additional treatment of pegbovigrastim, an immunostimulator, was evaluated. Enrofloxacin given alone stimulated a strong immune response, reduced the clinical manifestation and lung lessions of the M. bovis infection. In contrast the combination therapy appeared ineffective. In this experiment enrofloxacin given alone appeared to be the most effective treatment of the M. bovis affected calves, whereas co-administration with flunixin meglumine, and pegbovigrastim was not beneficial in this trial.
ISSN:1746-6148
1746-6148
DOI:10.1186/s12917-019-2122-3